Wire
Akebia Therapeutics Doses First Participants in Phase 1 Trial of AKB-9090 in Cardiac Surgery-Associated Acute Kidney Injury
Akebia Therapeutics (AKBA) said Monday that first participants have been dosed in its phase 1 trial of AKB-9090 for the treatment of cardiac surgery-associated acute kidney injury.The study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of AKB-9090 being administered intravenously in healthy adult participants, and will enroll up to 70 individuals, Akebia Therapeutics said.The company plans to report top line data from the study in early 2027, said Akebia Therapeutics' Chief Executive Officer John Butler in a statement.
$AKBA
